### Ischemic Vascular Disease (IVD): Use of Aspirin or another Antithrombotic (NQF 0068)

<table>
<thead>
<tr>
<th>EMeasure Name</th>
<th>Ischemic Vascular Disease (IVD): Use of Aspirin or another Antithrombotic</th>
<th>EMeasure Id</th>
<th>Pending</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version Number</td>
<td>1</td>
<td>Set Id</td>
<td>Pending</td>
</tr>
<tr>
<td>Available Date</td>
<td>No information</td>
<td>Measurement Period</td>
<td>January 1, 20xx through December 31, 20xx</td>
</tr>
<tr>
<td>Measure Steward</td>
<td>National Committee for Quality Assurance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endorsed by</td>
<td>National Quality Forum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Description</td>
<td>The percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1–November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had documentation of use of aspirin or another antithrombotic during the measurement year.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measure scoring Measure type</td>
<td>Proportion</td>
<td>Process</td>
<td></td>
</tr>
<tr>
<td>Rationale</td>
<td>This measure assesses the percentage of patients in a specific age demographic who were diagnosed with ischemic vascular disease (IVD) and demonstrated the utilization of aspirin or another antithrombotic to prevent coronary heart disease (CHD). IVD and related conditions had an estimated cost burden of $393.5 billion in 2005 (AHA 2005). The disease burden is also noteworthy, with CHD being an underlying or contributing cause of death for 451,300 people, accounting for 1 of every 5 deaths in the United States in 2004 (AHA 2008). The National Commission on Prevention Priorities (NCPP) determined that aspirin therapy is the most highly utilized and most effective clinical preventable service in preventing CHD (Maciosek 2006). Studies support this statement: aspirin therapy is shown to have directly reduced the odds of cardiovascular events among men by 14% and among women by 12% (Berger 2006). Additionally, aspirin use reduced the number of strokes by 20% and the number of myocardial infarctions and other vascular events by 30% (Weisman 2002). This measure facilitates long-term management of IVD through aspirin or another antithrombotic to prevent CHD.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Recommendation Statement</td>
<td>USPSTF: The U.S. Preventive Services Task Force (USPSTF) strongly recommends that clinicians discuss aspirin chemoprevention with adults who are at increased risk (5-year risk of greater than or equal to 3 percent) for coronary heart disease (CHD). Discussions with patients should address both the potential benefits and harms of aspirin therapy. (‘A’ recommendation) The USPSTF recommends the use of aspirin for men age 45 to 79 years when the potential benefit due to a reduction in myocardial infarctions outweighs the potential harm due to an increase in gastrointestinal hemorrhage (‘A’ recommendation). The USPSTF recommends the use of aspirin for women age 55 to 79 years when the potential benefit of a reduction in ischemic strokes outweighs the potential harm.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
harm of an increase in gastrointestinal hemorrhage. (‘A’ recommendation)

ADA: Use aspirin therapy (75–162 mg/day) as a secondary prevention strategy in those with diabetes with a history of CVD. (Level A). Use aspirin therapy (75–162 mg/day) as a primary prevention strategy in those with type 1 or 2 diabetes at increased cardiovascular risk, including those who are 40 years of age or who have additional risk factors (family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria). (Level A)

AHA/ACC: Start aspirin 75 to 162 mg and continue indefinitely in all patients with coronary and other vascular disease unless contraindicated. (Class I, Level A)

AHA/ASA: The use of aspirin is recommended for cardiovascular (including but not specific to stroke) prophylaxis among persons whose risk is sufficiently high for the benefits to outweigh the risks associated with treatment (a 10-year risk of cardiovascular events of 6% to 10%). (Class I: Level A)

ACCP: For long-term treatment after PCI, the guideline developers recommend aspirin, 75 to 162 mg/day. (Grade 1A) For long-term treatment after PCI in patients who receive antithrombotic agents such as clopidogrel or warfarin, the guideline developers recommend lower-dose aspirin, 75 to 100 mg/day. (Grade 1C+) For patients with ischemic stroke who are not receiving thrombolysis, the guideline developers recommend early aspirin therapy, 160 to 325 mg/day. (Grade 1A)

References


Definitions

Table of Contents

- Population criteria
- Data criteria (QDS Data Elements)
- Summary calculation

Please refer to the spreadsheet for this measure for detail regarding data criteria and code lists.

Population criteria
• **Initial Patient Population** =
  o AND: “Patient characteristic: birth date” (age) \( \geq 17 \) years to capture all patients who will reach the age of 18 during the “measurement period”;  
• **Denominator** =
  o OR: “Procedure performed: PTCA” (Percutaneous Transluminal Cardiac Angioplasty) 14 to 24 months before the “measurement end date”;  
  o OR:  
    • AND: “Encounter: encounter acute inpt” 14 to 24 months before the “measurement end date”;  
    • AND: “Diagnosis active: acute myocardial infarction” during “Encounter: encounter acute inpt”;  
  o OR:  
    • AND: “Encounter: encounter acute inpt” 14 to 24 months before the “measurement end date”;  
    • AND: “Procedure performed: CABG” (Coronary Artery Bypass Graft) 14 to 24 months before the “measurement end date”;  
  o OR:  
    • AND: “Encounter: encounter acute inpt and outpt” \( \leq 2 \) years before “measurement end date”;  
    • AND: “Diagnosis active: ischemic vascular disease” during “Encounter: encounter acute inpt and outpt”;  
• **Numerator** =
  o OR: “Medication dispensed: oral anti-platelet therapy”;  
  o OR: “Medication order: oral anti-platelet therapy”;  
  o OR: “Medication active: oral anti-platelet therapy”;  
• **Exclusions** =
  o None;  

**Data criteria (QDS Data Elements)**

• **Initial Patient Population** =
  o “Patient characteristic: birth date” using “birth date code list” before the beginning of the “measurement period”;  
• **Denominator** =
  o “Encounter: encounter acute inpt” using “encounter acute inpt code list” before the “measurement end date”;
 Encounter: encounter acute inpt and outpt” using “encounter acute inpt and outpt code list grouping” before “measurement end date”;
 • “Diagnosis active: acute myocardial infarction” using “acute myocardial infarction code list grouping” before the “measurement end date”;
 • “Diagnosis active: ischemic vascular disease” using “ischemic vascular disease code list grouping” before the “measurement end date”;
 • “Procedure performed: PTCA” (Percutaneous Transluminal Cardiac Angioplasty) using “PTCA code list grouping” before the “measurement end date”;
 • “Procedure performed: CABG” (Coronary Artery Bypass Graft) using “CABG code list grouping” before the “measurement end date”;

 Numerator =
 • “Medication dispensed: oral anti-platelet therapy” using “oral anti-platelet therapy code list” during “measurement period”;
 • “Medication order: oral anti-platelet therapy” using “oral anti-platelet therapy code list” during “measurement period”;
 • “Medication active: oral anti-platelet therapy” using “oral anti-platelet therapy code list” during “measurement period”;

 Exclusions =
 • None;

 Summary calculation

 Calculation is generic to all measures:
 • Calculate the final denominator by adding all that meet denominator criteria.
 • Subtract from the final denominator all that do not meet numerator criteria yet also meet exclusion criteria. Note some measures do not have exclusion criteria.
 • The performance calculation is the number meeting numerator criteria divided by the final denominator.
 • For measures with multiple patient populations, repeat this process for each patient population and report each result separately.
 • For measures with multiple numerators, calculate each numerator separately within each population using the paired exclusion.